150 related articles for article (PubMed ID: 19470510)
1. Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Kotsakis SD; Papagiannitsis CC; Tzelepi E; Tzouvelekis LS; Miriagou V
Antimicrob Agents Chemother; 2009 Aug; 53(8):3520-3. PubMed ID: 19470510
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Val211Gly substitution on molecular dynamics of the CMY-2 cephalosporinase: implications on hydrolysis of expanded-spectrum cephalosporins.
Kotsakis SD; Tzouvelekis LS; Petinaki E; Tzelepi E; Miriagou V
Proteins; 2011 Nov; 79(11):3180-92. PubMed ID: 21989938
[TBL] [Abstract][Full Text] [Related]
3. Interactions of oximino-substituted boronic acids and β-lactams with the CMY-2-derived extended-spectrum cephalosporinases CMY-30 and CMY-42.
Kotsakis SD; Caselli E; Tzouvelekis LS; Petinaki E; Prati F; Miriagou V
Antimicrob Agents Chemother; 2013 Feb; 57(2):968-76. PubMed ID: 23229484
[TBL] [Abstract][Full Text] [Related]
4. Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.
Kotsakis SD; Miriagou V; Vetouli EE; Bozavoutoglou E; Lebessi E; Tzelepi E; Tzouvelekis LS
Antimicrob Agents Chemother; 2015 Dec; 59(12):7894-8. PubMed ID: 26438499
[TBL] [Abstract][Full Text] [Related]
5. Genetic, Biochemical, and Structural Characterization of CMY-136 β-Lactamase, a Peculiar CMY-2 Variant.
Zavala A; Retailleau P; Elisée E; Iorga BI; Naas T
ACS Infect Dis; 2019 Apr; 5(4):528-538. PubMed ID: 30788955
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
[TBL] [Abstract][Full Text] [Related]
7. Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.
Endimiani A; Doi Y; Bethel CR; Taracila M; Adams-Haduch JM; O'Keefe A; Hujer AM; Paterson DL; Skalweit MJ; Page MG; Drawz SM; Bonomo RA
Biochemistry; 2010 Feb; 49(5):1014-23. PubMed ID: 19938877
[TBL] [Abstract][Full Text] [Related]
8. An engineered disulfide bond between residues 69 and 238 in extended-spectrum beta-lactamase Toho-1 reduces its activity toward third-generation cephalosporins.
Shimizu-Ibuka A; Matsuzawa H; Sakai H
Biochemistry; 2004 Dec; 43(50):15737-45. PubMed ID: 15595829
[TBL] [Abstract][Full Text] [Related]
9. Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime.
Cantu C; Huang W; Palzkill T
J Biol Chem; 1996 Sep; 271(37):22538-45. PubMed ID: 8798421
[TBL] [Abstract][Full Text] [Related]
10. Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis.
Kimura S; Ishiguro M; Ishii Y; Alba J; Yamaguchi K
Antimicrob Agents Chemother; 2004 May; 48(5):1454-60. PubMed ID: 15105092
[TBL] [Abstract][Full Text] [Related]
11. Contribution of asparagine 346 residue to the carbapenemase activity of CMY-2 β-lactamase.
Dahyot S; Broutin I; de Champs C; Guillon H; Mammeri H
FEMS Microbiol Lett; 2013 Aug; 345(2):147-53. PubMed ID: 23763375
[TBL] [Abstract][Full Text] [Related]
12. The catalytic efficiency (kcat/Km) of the class A beta-lactamase Toho-1 correlates with the thermal stability of its catalytic intermediate analog.
Nitanai Y; Shimamura T; Uchiyama T; Ishii Y; Takehira M; Yutani K; Matsuzawa H; Miyano M
Biochim Biophys Acta; 2010 Apr; 1804(4):684-91. PubMed ID: 19883800
[TBL] [Abstract][Full Text] [Related]
13. Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.
Papp-Wallace KM; Winkler ML; Gatta JA; Taracila MA; Chilakala S; Xu Y; Johnson JK; Bonomo RA
Antimicrob Agents Chemother; 2014 Aug; 58(8):4290-7. PubMed ID: 24820081
[TBL] [Abstract][Full Text] [Related]
14. Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.
Dahyot S; Mammeri H
Antimicrob Agents Chemother; 2012 Mar; 56(3):1151-6. PubMed ID: 22232281
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate.
Doi Y; Shibata N; Shibayama K; Kamachi K; Kurokawa H; Yokoyama K; Yagi T; Arakawa Y
Antimicrob Agents Chemother; 2002 Aug; 46(8):2427-34. PubMed ID: 12121914
[TBL] [Abstract][Full Text] [Related]
16. CMY-42, a novel plasmid-mediated CMY-2 variant AmpC beta-lactamase.
Hentschke M; Kotsakis SD; Wolters M; Heisig P; Miriagou V; Aepfelbacher M
Microb Drug Resist; 2011 Jun; 17(2):165-9. PubMed ID: 21388298
[TBL] [Abstract][Full Text] [Related]
17. N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.
Skalweit MJ; Li M; Conklin BC; Taracila MA; Hutton RA
Antimicrob Agents Chemother; 2013 Apr; 57(4):1596-602. PubMed ID: 23318801
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum cephalosporinases: structure, detection and epidemiology.
Nordmann P; Mammeri H
Future Microbiol; 2007 Jun; 2(3):297-307. PubMed ID: 17661704
[TBL] [Abstract][Full Text] [Related]
19. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling.
Huletsky A; Knox JR; Levesque RC
J Biol Chem; 1993 Feb; 268(5):3690-7. PubMed ID: 8429044
[TBL] [Abstract][Full Text] [Related]
20. A triple mutant in the Ω-loop of TEM-1 β-lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis.
Stojanoski V; Chow DC; Hu L; Sankaran B; Gilbert HF; Prasad BV; Palzkill T
J Biol Chem; 2015 Apr; 290(16):10382-94. PubMed ID: 25713062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
